---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-089615"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-09-19T23:59:59+00:00"
generated_at: "2026-05-17T06:08:36.061518+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology doubles share reserve to 30M under 2024 equity plan; issues 360K warrants

## Summary
- Board approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.
- Issued warrants to purchase 360K shares of common stock at $2.1875, exercisable March 10, 2026, expiring 2031.
- Warrants issued in private placement under Section 4(a)(2) to a financial advisor.
- No other changes were made to the 2024 Plan besides the share increase.

## SEC filing metadata
- accession: 0001213900-25-089615
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025089615/0001213900-25-089615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025089615/ea0257909-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-089615
- JSON: https://secwatch.observer/filing/0001213900-25-089615.json
- Plain text: https://secwatch.observer/filing/0001213900-25-089615.txt

## Key facts
- Equity Issuances
  CITIUS ONCOLOGY, INC. issued up to 360,000 shares of common stock of warrant to a financial advisor.
  - Security: warrant
  - Shares: up to 360,000 shares of common stock
  - Purchaser: a financial advisor
  source text: On September 19, 2025, Citius Oncology, Inc. (the “Company) issued to a financial advisor warrants to purchase up to 360,000 shares of our common stock with an exercise price of $2.1875 per shares, that are exercisable on March 10, 2026, and that expire on March 10, 2031.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000121390025089615/0001213900-25-089615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.